Fred Hutchinson Cancer Center Facing Workforce Reductions Amid Funding Challenges and NIH Policy Changes
Seattle’s Fred Hutchinson Cancer Center has implemented workforce reductions this week, with layoffs affecting multiple departments including HIV research and information technology. The precise number of affected employees was not disclosed by the organization, which maintains a workforce of over 5,700 people.
The reduction in HIV-related positions stems from decreased federal grant funding, according to organizational spokesperson Christina VerHeul. Separately, the IT department underwent what VerHeul described as a strategic reorganization, impacting staff members whose tenure ranged from recent hires to decades-long veterans.
The layoffs come amid broader challenges facing American health research institutions under the Trump administration’s funding policies. The administration has ordered a 35% reduction in federal health agency contract spending, including National Institutes of Health (NIH) funding, which serves as a crucial source of support for research organizations nationwide.
Nearly 800 NIH grants have been canceled across the country, resulting in the elimination of more than $1.1 billion in research and trial funding. An additional $2 billion in promised grant funds has been withheld from recipients, according to U.S. Senator Patty Murray (D-Wash.), who voiced her concerns during a recent Senate
Appropriations Committee hearing on biomedical research.
Fred Hutch faces particular challenges from a proposed universal cap of 15% on indirect costs announced by the NIH in February. These costs cover essential operations including utilities, IT support,
administration, and research-related services. The organization’s current negotiated rate for indirect costs is 76%, and the proposed cap would eliminate approximately $125 million in annual support. A temporary restraining order against the universal cap has been granted by a U.S. District Court judge.
Dr. Tom Lynch, Fred Hutch’s president and director, has warned that the implementation of the indirect cost cap would severely impact the institution’s research capabilities. The center conducted more than 450 treatment trials in its previous fiscal year, many supported by NIH funding and offering critical options for patients with
difficult-to-treat cancers.
The current layoffs follow a previous workforce reduction in June 2020, when the organization eliminated 76 positions and 81 vacant roles due to COVID-19’s economic impact. Recent cuts to the IT department have raised concerns about potential disruptions to the center’s operations, particularly in areas supporting clinical trials and patient care. The department provides essential services including help desk support for urgent technology issues affecting patient care and continues to manage projects related to the 2022 merger between Fred Hutch and Seattle Cancer Care Alliance.
The administration has defended its funding reductions as necessary budget-cutting measures targeting wasteful spending. However, the cuts have faced significant criticism from research institutions and lawmakers. A recent controversy emerged when the administration moved to terminate a long-running women’s health initiative coordinated by Fred Hutch. While the Department of Health and Human Services reportedly reversed this decision following public outcry, Fred Hutch officials indicate they have not received official confirmation of the program’s reinstatement.
These developments occur as Fred Hutch continues to navigate significant organizational changes, including the relatively recent appointment of Omer Awan, formerly of Atrium Health, as Chief Information Officer in September. The institution maintains its role as a leader in both cancer research and HIV studies, with
approximately 20% of its federally funded research focusing on HIV-related initiatives, including clinical trials and
multi-institution collaborations such as the HIV Vaccine Trials Network.
